Objectives: Although clinical practice guidelines recommend standard cefazolin antimicrobial prophylaxis (AP) dosing for cardiac surgery, limited data exist as to whether adequate concentrations are achieved in this patient population. The goal of our study was to characterize intraoperative cefazolin concentrations particularly at wound closure with regards to maintaining target cefazolin closure concentrations 40 mg/L.
Introduction
Guidelines for antimicrobial prophylaxis (AP) recommend cefazolin regimens consisting of 1, 2 or 3 g within 60 min prior to incision and every 4 h during surgery. 1 The goal is to maintain 'adequate serum and tissue concentrations during the period of potential contamination' thereby inhibiting possible pathogens and preventing surgical site infections (SSIs). 1 Given the significant alterations in cefazolin pharmacokinetics during cardiac surgery requiring cardiopulmonary bypass (CPB), it is important to study AP regimens in this patient population. Although alternative cefazolin regimens are described in the literature (Table S1 , available as Supplementary data at JAC Online), to our knowledge, this is the first study of concentrations achieved during cardiac surgery with CPB using the standard cefazolin AP regimen.
The goal was to characterize intraoperative cefazolin concentrations particularly at wound closure with regards to maintaining target closure concentrations 40 mg/L. The hypothesis was that target cefazolin concentrations for AP would not be achieved in all patients undergoing cardiac surgery with CPB.
Methods
The study was approved by Subject characteristics including medical and surgical history were documented along with antimicrobial therapy or hospitalization within 3 months. Information regarding the cardiac surgery including type of procedure, relevant time points, fluid administration and loss, intraoperative complications and re-explorations following primary wound closure was detailed. Relevant clinical and laboratory data were collected from hospital medical records, including those from the preoperative assessment clinic and operating room.
Participants received cefazolin AP according to protocol (i.e. 1 or 2 g based on body weight administered within 60 min prior to incision, every 4 h during surgery and every 8 h for 48 h postoperatively). All cefazolin doses and timings were recorded. Cefazolin doses were also represented per kg of total body weight or dosing weight (DW) for subjects with class II or III obesity (BMI 35 kg/m 2 ); DW (kg) " ideal body weight ! 0.3(total body weight # ideal body weight) and ideal body weight was 50 kg for males or 45 kg for females plus 2.3 kg for every inch (2.54 cm) over 5 feet (152.4 cm). 3 Blood samples were collected 30 min after the preoperative cefazolin dose (peak sample), prior to intraoperative cefazolin doses (intraoperative trough sample) and within 15 min of wound closure (closure sample). Total cefazolin concentrations were measured using a previously developed LC-MS/MS assay. 4 In our study, the assay was validated from 4 to 100 mg/L with 93% accuracy and 97% precision using the methods outlined in the FDA Guidance for Industry: Bioanalytical Method Validation document. 5 Total intraoperative trough and closure concentrations were characterized and evaluated against a target threshold of 40 mg/L (8 mg/L unbound, assuming 80% protein binding). Univariate analysis was conducted to identify associations between subject-, surgery-and AP-related variables with regards to target closure concentration utilizing the twotailed Student's t-test, Mann-Whitney U-test, Pearson v 2 test or Fisher's exact test, as appropriate. Significant variables (P , 0.05) were included in a multivariate analysis using backward stepwise, binary logistic regression modelling. The models were evaluated using Akaike Information Criteria and tested for goodness-of-fit. All statistical analyses were conducted using SYSTAT 12 (Systat Software Inc., San Jose, CA, USA).
Results
Sixty patients were enrolled, and 55 subjects completed the study. Four patients did not undergo surgery and one subject was removed owing to an immediate hypersensitivity reaction to the preoperative cefazolin dose. Subject characteristics are detailed in Table 1 . Most subjects (78.2%, 43 of 55) received intermittent 2 g doses of cefazolin. Only 23.6% (13 of 55) of subjects received a single preoperative dose, whereas 67.3% (37 of 55) received one and 9.1% (5 of 55) received two or more intraoperative doses. Preoperative doses (21.4+4.4 mg/kg DW ) were administered 35+14 min prior to incision, and 94.5% (52 of 55) were within 60 min. The subsequent intraoperative doses (n " 48) were given every 3.9+0.3 h.
A total of 134 plasma concentrations including 53 peak, 30 intraoperative trough and 51 closure concentrations were analysed. The mean total cefazolin peak concentration was 145.2+36.6 mg/L and the total intraoperative trough concentration was 46.5+17. In univariate analyses, lower body weight (P , 0.0001), shorter duration of surgery (P , 0.0001) and female gender (P " 0.04) were significantly associated with cefazolin closure concentrations ,40 mg/L (Table 2) . Only body weight (P " 0.027) and duration of surgery (P " 0.045) remained in the multivariate model. These variables were incorporated into a total cefazolin exposure (preoperative and intraoperative doses) that was normalized for DW and duration of surgery. In subjects with closure concentrations ,40 mg/L and 40 mg/L, the cefazolin dose for every hour of surgery (intermittent dosing) was 5.8+1.7 mg/kg DW and 8.2+2.0 mg/kg DW , respectively (P " 0.03). Based on classification and regression tree (CART) analysis, a cefazolin exposure of Cefazolin concentrations during cardiac surgery JAC 7.6 mg/kg DW for every hour of surgery was a significant threshold for achieving target closure concentrations.
Discussion
Our study characterized cefazolin concentrations achieved during cardiac surgery with CPB using the standard AP regimen. There was significant variability in cefazolin concentrations most notably at wound closure when values ranged from 32 to 222 mg/L ( Figure S1 ). Almost 10% of cefazolin closure concentrations were below the target of 40 mg/L, as were 40% of intraoperative trough concentrations at the scheduled re-dosing time. This is an important observation given the association between low AP closure concentrations and increased risk of SSI. 6 We evaluated total cefazolin closure concentrations against a target of 40 mg/L (8 mg/L unbound) for effective AP. Although reports of cefazolin protein binding in this population range from 40% to 80%, we used the latter as the most conservative estimate of unbound (active) drug. [7] [8] [9] [10] An unbound concentration of 8 mg/L is consistent with the CLSI susceptible breakpoint for Enterobacteriaceae spp. before being lowered to 2 mg/L for improved detection of ESBLs.
11 It is also the last susceptible breakpoint for antistaphylococcal cephalosporins before inferring susceptibility from oxacillin (or cefoxitin) testing for methicillin resistance. Finally, an unbound concentration of 8 mg/L represents the threshold for bactericidal activity (i.e. four times the MIC) against the common susceptible skin flora with MICs 2 mg/L.
Our study found that lower body weight and shorter duration of surgery were significant predictors of below-target closure concentrations in patients undergoing cardiac surgery with CPB. Lower body weight was also associated with intermittent 1 g doses thereby confirming that at least 2 g should be used regardless of weight. The association between shorter duration of surgery and lower closure concentration was another important observation. Given that re-dosing did comply with the 'every 4 h' recommendation, our findings suggest that more frequent re-dosing every 3 h should be considered for patients with normal renal function. Finally, our analysis of total cefazolin exposure incorporated patient weight and duration of surgery into a modifiable variable that could be used to optimize cefazolin AP regimens. The relationship between body or dosing weight, re-dosing interval and intermittent cefazolin doses required to maintain closure concentrations 40 mg/L in our study population are shown in Table S2 . Using the significant threshold of 7.6 mg/kg DW for every hour of surgery, these data also support a cefazolin AP regimen consisting of at least 2 g preoperatively and every 3 h during surgery.
A limitation of our study was the analysis of total as opposed to unbound (active) cefazolin concentrations. Similar to other studies, cefazolin closure concentrations were evaluated against targets that exceed the MICs for potential pathogens as opposed to those directly associated with clinical outcome. The limitation is indicative of the paucity of pharmacokinetic/pharmacodynamic research in the area of AP for surgery. Finally, as our study was conducted in subjects with relatively normal renal function, the findings do not apply to patients with significant renal insufficiency.
In conclusion, the standard cefazolin AP regimen was not reliable in maintaining target closure concentrations 40 mg/L in patients with normal renal function undergoing elective cardiac surgery with CPB. In our study, a cefazolin exposure of 7.6 mg/ kg DW for every hour of surgery (intermittent dosing) was required to achieve target closure concentrations. Data are presented as n (%) or mean + SD.
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